BrainStorm

March 31, 2014

How Close Are We to an Approved Treatment? - Bernard Munos

Thumbnail

How Close Are We to an Approved Treatment? - Bernard Munos

About This Episode

A discussion with Bernard Munos, Founder of InnoThink, and named one of the 25 most influential people in biopharma by FiercePharma.  He discussed his analysis of the drug pipeline, the status of drugs in it, as well as his recommendations for how we can organize research more effectively and lower the cost of innovation and reduce the risk of failure so that we can get to a cure faster and at lower cost.

This call was made possible by the generous support of the Zickler Family Foundation.

BrainStorm Feed

100
December 16, 2025 | 22:29

2025 Year in Review and Predictions for 2026 with George Vradenburg

George Vradenburg, Chairman and Founder of UsAgainstAlzheimer's, sits down with host Meryl Comer for a comprehensive look at the state of Alzheimer's research, advocacy, and care in 2025.
LISTEN NOW
99
December 2, 2025 | 16:32

The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s Platform (part 2)

In part 2 John Dwyer, CEO of the Global Alzheimer's Platform (GAP), and BrainStorm host Meryl Comer discuss transforming Alzheimer's research and clinical trials.
LISTEN NOW
98
November 18, 2025 | 16:52

The Future of Alzheimer's Trials: Bringing Cutting-Edge Research to Every Community - John Dwyer, CEO of The Global Alzheimer's Platform

John Dwyer, CEO of the Global Alzheimer's Platform (GAP), highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities.
LISTEN NOW